Director Declaration Sale of Shares

Evolutec Group plc ("Evolutec" or "the Company") Pursuant to rule 17 of AIM Regulations (Schedule 5), Dr David Philip Bloxham (Chairman) disclosed on 17 March 2008 that on the same date he sold 33,036 Ordinary 10p Shares in Evolutec Group plc at a price of 18p per share. The beneficial owner of the shares was the David Philip Bloxham SIPP. After this transaction Dr Bloxham holds 103,472 Ordinary Shares in the Company. 17 April 2008 Evolutec is listed on the AIM market of the London Stock Exchange and developed therapeutics originally isolated from the saliva of ticks. Following the unsuccessful outcome of Phase II clinical trials on its lead clinical trail candidate, the Company licensed its intellectual property to third parties and is now focussing all its activities on the identification of a single investment opportunity. This will take advantage of Evolutec's AIM listing and its cash and cash equivalent reserve. Safe Harbour statement: this news release may contain forward-looking statements that reflect the current expectations of the Company regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's strategy, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions. ---END OF MESSAGE---